MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.330
+0.140
+6.39%
After Hours: 2.400 +0.07 +3.00% 19:57 09/25 EDT
OPEN
2.140
PREV CLOSE
2.190
HIGH
2.400
LOW
2.110
VOLUME
441.83K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
0.5500
MARKET CAP
38.27M
P/E (TTM)
-1.2993
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Precipio launches leukemia diagnostic panel
Precipio ([[PRPO]] +5.9%) has launched its HemeScreen AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering.Laboratories can test that patient sample
Seekingalpha · 4d ago
Precipio Launches Proprietary HemeScreen AML Molecular Panel
-Reuters
Reuters · 4d ago
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
Panel of clinically critical genes can yield same-day results outperforming major competitorsNEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid Leukemia) panel
GlobeNewswire · 4d ago
Agenus, Achieve Life Sciences leads gainers, Satsuma Pharmaceuticals, Precipio among losers
Gainers:  Agenus (AGEN) +13%, Achieve Life Sciences (ACHV) +7%, Agile Therapeutics (AGRX) +7%, Akouos (AKUS) +7%, Adial Pharmaceuticals (ADIL) +6%.Losers: Satsuma Pharmaceuticals (STSA) -75%, Precipio (PRPO) -22%, Sutro Biopharma (STRO) -18%, Athenex (ATNX) -16%, Spero Therapeutics (SPRO) -15%.
Seekingalpha · 09/10 15:10
Mid-Morning Market Update: Markets Open Higher; RH Tops Q2 Expectations
Following the market opening Thursday, the Dow traded up 0.57% to 28099.81 while the NASDAQ rose 1.41% to 11298.53. The S&P also rose, gaining 0.71% to 3,423.16.
Benzinga · 09/10 14:20
TRQ, CSIQ among premarket losers
Turquoise Hill Resources (TRQ) -21% after announcing an update on funding discussions with Rio Tinto.Precipio (PRPO) -17%.Muscle Maker (GRIL) -14%.GameStop (GME) -10% after Q2 earnings fall short of expectations.Athenex (ATNX) -8% after pricing stock offering.FuelCell Energy
Seekingalpha · 09/10 12:18
Precipio up 8% ahead of COVID-19 strategy update
Nano cap Precipio (PRPO) perks up 8% premarket on light volume ahead of today's conference call (5:00 pm ET) on its COVID-19 activities and strategy. CEO Ilan Danieli will address questions sent
Seekingalpha · 09/09 11:25
Precipio, AnPac Bio-Medical Science leads the gainers pack, Cardiff Oncology, Fulgent Genetics amongst major losers
Gainers: Precipio (PRPO) +15%, AnPac Bio-Medical Science Co (ANPC) +15%, The Cooper Companies (COO) +7%, Entasis Therapeutics Holdings (ETTX) +6%, 89bio (ETNB) +5%.Losers: Cardiff Oncology (CRDF) -26%, Heat Biologics (HTBX) -16%, Fulgent Genetics (FLGT) -15%, Sorrento Therapeutics (SRNE) -13%, Xeris Pharmaceuticals (XERS) -12%.
Seekingalpha · 09/04 15:04
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of PRECIPIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRPO stock price target is 4.150 with a high estimate of 6.30 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 23
Institutional Holdings: 238.50K
% Owned: 1.45%
Shares Outstanding: 16.43M
TypeInstitutionsShares
Increased
1
7
New
9
-149.09K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.83%
Healthcare Equipment & Supplies
+2.01%
Key Executives
Chairman/Director
Douglas Fisher
President/Chief Executive Officer/Director
Ilan Danieli
Chief Financial Officer
Carl Iberger
Vice President/Director of Sales
Douglas Sites
Other
Ori Karev
Director
David Cohen
Director
Mark Rimer
Director
Richard Sandberg
Independent Director
Jeffrey Cossman
Independent Director
Kathleen LaPorte
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRPO
Precipio, Inc. is a cancer diagnostics company providing diagnostic products and services to the oncology market. The Company’s platform is designed to provide physicians and their patients access to necessary technology in order to provide diagnoses. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a proprietary culture media that addresses the problem of selective culturing-by creating a universal media that enables simultaneous culturing of hematopoietic cell lineages. ICP is a specimen enrichment technology that increases the sensitivity of molecular based tests. The Company has developed a screening panel for genes in one rapid scanning panel, HemeScreen.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.